Editorial
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Nov 27, 2016; 6(3): 119-125
Published online Nov 27, 2016. doi: 10.5411/wji.v6.i3.119
Myeloid derived suppressor cells in breast cancer: A novel therapeutic target?
Rebekah M Weston, Cordula M Stover
Rebekah M Weston, Cordula M Stover, Department of Infection, Immunity and Inflammation, College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester LE1 9HN, United Kingdom
Cordula M Stover, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 9HN, United Kingdom
Author contributions: Weston RM researched the field, extracted and compiled the findings; Stover CM discussed the evaluation and revised the paper.
Conflict-of-interest statement: The authors declare no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Cordula M Stover, PhD, Associate Professor, Department of Infection, Immunity and Inflammation, University of Leicester, Maurice Shock Medical Sciences Building, University Road, Leicester LE1 9HN, United Kingdom. cms13@le.ac.uk
Telephone: +44-116-2525032 Fax: +44-116-2525030
Received: August 26, 2016
Peer-review started: August 29, 2016
First decision: September 27, 2016
Revised: October 16, 2016
Accepted: October 25, 2016
Article in press: October 27, 2016
Published online: November 27, 2016
Core Tip

Core tip: Breast cancer is the most common cancer among women in the United Kingdom; there were 44540 new cases of invasive carcinoma in 2013. The incidence rate is 169.8:100000, an increase of 5.5% in 10 years. Despite significant advances in the detection and treatment of breast cancer, breast cancer still results in 11600 deaths a year; the second highest number of cancer deaths in women. With increased appreciation of the sustaining importance of cells in the tumour microenvironment, in particular myeloid derived suppressor cells, their targeting is being considered as a novel treatment approach.